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Abstract
Background and Purpose: Both endothelial progenitor cells (EPC) and markers of neuroinflammation are
candidate biomarkers for stroke severity and outcome prediction. A relationship between EPC and
neuroinflammatory markers in early stroke is not fully elucidated. The objectives were to investigate correlations
between EPC and neuroinflammation markers (adhesion molecules ICAM-1, VCAM-1, E-selectin, tumor necrosis
factor (TNF)-a, interleukin (IL)-6, endothelin (ET)-1, markers of tissue injury (matrix metalloproteinases (MMP)-9 and
tissue inhibitor of matrix metalloproteinases (TIMP)-1) in early stroke patients.
Methods: We prospectively recruited symptomatic patients with ischemic cerebrovascular disease. We assessed
stroke severity by using of acute (diffusion-weighted imaging (DWI) and final lesion volumes (fluid attenuated
inversion recovery (FLAIR). We measured serum soluble ICAM-1, VCAM-1, E-selectin, MMP-9, TIMP-1 and plasma
TNF-a, IL-6, ET-1 by ELISA, and quantified EPC in mononuclear fraction of peripheral blood on days 1 and 3 in 17
patients (mean(SD) age 62(14), with admission National Institutes of Health Stroke Scale (NIHSS) 10(8)) selected
from 175 patients with imaging confirmed ischemic stroke. Non-parametric statistics, univariate and multivariate
analysis were used.
Results: Only ICAM-1 inversely correlated with EPC subset CD133+CD34+ on day 1 (Spearman r = -0.6, p < 0.01)
and on day 3 (r = -0.967, p < 0.001). This correlation remained significant after adjustment for age and NIHSS (beta
-0.992, p < 0.004), for glucose and systolic blood pressure (beta -0.86, p < 0.005), and for white blood cells and
hematocrit (beta -1.057, p < 0.0001) on day 3. MMP-9 (r = 0.509, p < 0.04) and MMP-9/TIMP-1 (r = 0.59, p < 0.013)
on day 1 correlated with acute lesion volume. Both IL-6 (r = 0.624, p < 0.01) and MMP-9/TIMP-1 (r = 0.56, p < 0.02)
correlated with admission NIHSS.
Conclusion: Our study showed that high ICAM-1 is associated with low CD133+CD34+subset of EPC. Biomarkers
of neuroinflammation may predict tissue injury and stroke severity in early ischemia.
Background
Stroke is a devastating condition and a second leading
cause of death worldwide. Usefulness of blood biomar-
kers for evaluation of stroke severity and outcome pre-
diction represents an emerging field of biomedical
research [1]. Numerous molecular biomarkers have been
investigated, however, due to complexity of stroke
pathophysiology [2,3], no single biomarker has been yet
established, and new candidate biomarkers are needed.
Endothelial progenitor cells (EPC) are participants in a
reparative angiogenesis [4] and may serve as markers of
acute phase stroke severity [5]. Increased EPC predict
favorable stroke outcome [6] and have a potential for
outcome prediction of cardiovascular diseases [7,8]. EPC
are activated through various angiogenic signals, such as
vascular endothelial factor, angiopoietin- 2, stromal-
derived factor-1a [9-11] released by hypoxic cells, and
are mobilized from bone marrow after activation of
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recruited to sites of vessel injury to aid endothelial
recovery. After ischemic tissue injury, numerous cyto-
kines, growth factors and chemokines (tumor necrosis
factor (TNF)-alfa, interleukins (IL), adhesion molecules,
endothlelins (ET)) are released locally [2,3,13]. They can
contribute to neuroinflammation, and they can be sub-
sequently detected in peripheral blood [12,13]. Biomar-
kers of neuroinflammation [14-18] and of tissue damage
[19,20] are extensively studied as markers of stroke
severity and for outcome prediction. However, the rela-
tionship of neuroinflammtory factors and severity of tis-
sue injury to rate of neovascularization propagated by
EPC in acute ischemia is currently unknown.
We hypothesized that pronounced neuroinflammation
inhibits neovascularization in acute ischemia, and EPC
levels are inversely related to of neuroinflammatory mar-
kers in early ischemic stroke patients. The first objective of
this study was to determine correlations between EPC and
major cellular and cytokine biomarkers of neuroinflamma-
tion (intercellular adhesion molecule (ICAM)-1, vascular
adhesion molecule (VCAM)-1, E-selectin, TNF-a,I L - 6 ,
endothelin (ET)-1), and tissue injury/remodeling (MMP-9)
in early stroke. The second objective was to evaluate rela-
tion of these biomarkers to stroke severity.
This report demonstrates that ICAM-1 is inversely
correlated with CD133+CD34+ subset of EPC on both
days 1 and 3 after stroke onset. Marker of tissue injury
MMP-9 and pro-inflammatory cytokine IL-6 were asso-
ciated with acute lesion volume and with admission
National Institutes of Health Stroke Scale (NIHSS).
Patients And Methods
Study design
This is a prospective pilot study of consecutive patients
with imaging confirmed acute stroke admitted to the
single stroke center at the Washington Hospital Center
(WHC) between October 2008 and May 2009, whose
first MRI imaging was within 24 hr of the time of last
seen normal (LSN).
Ethical approval
The study was approved by the NIH and WHC IRB (Insti-
tutional Review Board). Written informed consent was
obtained from all patients participating in the study
according to the institutional guidelines of NIH and
WHC.
Study population and enrollment criteria
A group of 323 consecutive patients referred upon suspi-
cion of an acute cerebrovascular event. After accurate
evaluation, forty (12%) of these patients were diagnosed
with hemorrhagic stroke, 13 (4%) with TIA, 96 (30%)
with stroke mimics (non-ischemic ethiology), and 175
(54%) had imaging confirmed ischemic stroke. Forty-one
(23%) of the admitted ischemic stroke patients partici-
pated in the Natural History Protocol “Evaluation, Patho-
genesis, and Treatment of Patients with or at Risk for
Cerebrovascular Disease”, which is a prospective observa-
tional study including patients 18 years old or older with
suspected acute stroke or TIA. After signing informed
consent the participants undergo serial brain MRI and
blood draws. The patients were included consecutively.
Exclusion criteria were as follows: 1) contraindications
to MRI, 2) latency form last seen normal (LSN) to blood
draws more than 72 hours, 3) signs or symptoms of hema-
tological, hepatic, infectious diseases, active malignancy, or
known recent surgery, which may interfere with levels of
the studied biomarkers, 4) peripheral vessel status that did
not allow blood collection. Blood collection was performed
on working hours (Monday through Friday) that led to
lost of a few patients otherwise consented for the Natural
History Protocol. The final study population included 17
patients (10% of all ischemic stroke patients) and did not
differ significantly from the total stroke cohort admitted to
the hospital regarding demographics, medication, or stroke
subtypes. The modified National Institutes of Health
Stroke Scale score was performed within 30 min the time
of initial brain MRI.
Brain MRI imaging and lesion volume measurements
MRI was performed using a 3T (Philips Medical Systems)
clinical scanner [21]. Lesion volumes were measured
from diffusion weighted image (DWI) and fluid attenu-
ated inversion recovery (FLAIR) using a semi-automated
quantitative method [22]. We used acute (DWI) and final
infarct volumes (FLAIR) as surrogate markers of stroke
severity. Growth of lesion volume was calculated as a dif-
ference between final FLAIR and baseline DWI lesion
volumes. Baseline DWI (baseline lesion volume) was per-
formed at 9 ± 8 hr after LSN. Day 1 DWI was performed
at 37 ± 19 hr and FLAIR (final lesion volume) was per-
formed at 10 ± 13 days after LSN.
Sample collection
Peripheral blood was collected at 31 ± 13 hr (day 1) and
76 ± 29 hr (day 3) after LSN. Blood was collected by veni-
puncture in 4 Vacutainer CPT (Cell Preparation Tube,
BD, Franklin Lakes, NJ) and centrifuged at 2000xg for
25 minutes. The mononuclear layer was isolated and
resuspended in autologous plasma containing 10%
dimethyl sulfoxide (DMSO) and stored at -80°C until
EPC analysis [23]. Plasma was separated and stored at
-80°C until cytokine measurements.
Measurements of biomarkers
EPC populations were identified using combinations of
surface markers (CD34+, CD133+, VEGFR2+). Briefly,
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6 mononuclear cells were incubated in 120 μLb u f -
fered saline containing 2% BSA with 20 μL Fc-blocking
agent (Miltenyi Biotech, Auburn, CA) for 10 minutes at
25°C to inhibit non-specific binding of antibodies. There-
after, the cells were incubated at 4°C for 30 minutes with
20 μL CD133/AC133-PE (Miltenyi Biotech, Auburn,
CA), 20 μL VEGFR2-FITC (R&D Systems, Minneapolis,
MN) and 20 μL CD34-ECD (Beckman Coulter, Brea, CA)
in a total volume of 200 μL. The cells were washed twice
before resuspension in 400 μL of stain buffer (BD Bios-
ciences, Franklin Lakes, NJ). Just prior to analysis on a
FACS Vantage SE (BD Biosciences), DAPI nuclear dye
was added to the cell suspension to allow for viability gat-
ing that was constantly 70 ± 3%, across the two collection
timepoints for all patients. Finally, a minimum of 1 × 10
6
live cells were collected, and FACS analysis was per-
formed in triplicate for each sample. Medians of three
measurements were calculated, and the resulting EPC
counts are expressed as a percentage of total mononuc-
lear cells in each sample.
Serum total MMP-9 (minimal detectable value (MDV)
0.156 ng/mL), TIMP-1 (MDV 0.08 ng/mL), E-selectin
(MDV 0.009 ng/mL), ICAM-1 (MDV 0.096 ng/mL),
VCAM-1 (MDV 0.6 ng/mL) and plasma IL-6 (MDV
0.7 pg/mL), and ET-1 (MDV 1.0 pg/mL) were measured
by commercially available sandwich enzyme-linked
immunoassays (ELISA) (Quantikine, R&D Systems Inc
Minneapolis, MN) in duplicate samples according to the
manufacturer instructions. TNF-a was measured in
duplicate by ultrasensitive ELISA (ALPCO, NH), (MDV
0.5 pg/mL). MMP-9/TIMP-1 ratios were calculated.
Statistical analysis
D e s c r i p t i v ea n df r e q u e n c ya nalysis was obtained for all
data. Because biomarkers were not normally distributed,
data are presented as median with range. Correlations
were made using the two-tailed Spearman rank test.
Differences between groups were assessed either by the
two-tailed Mann-Whitney test or the Kruskall-Wallis test.
Differences between repeated measurements were calcu-
lated by the two-tailed Wilcoxon rank test. Linear regres-
sion was used for adjustments for major risk stroke factors
and factors potentially influencing biomarkers’ and EPC
levels. SPSS software version 16.0 was used. The level of
significance was set up at p < 0.05.
Results
Patients’ characteristics
In total, 17 patients from the total cohort of stroke
patients met the inclusion criteria (10% of all ischemic
stroke patients). The study population did not differ sig-
nificantly from the total stroke cohort admitted to the
hospital in respect to demographics or medication
(Table 1). Accordingly to the TOAST criteria the stroke
types were diagnosed as follows: three patients (18%)
had large artery atherosclerosis, three (18%) had small
artery occlusion, seven (41%) had cardioembolic stroke,
three (18%) had other determined causes, and one
patient (6%) had an undetermined cause of stroke.
Hence, the percentage of cardioembolic strokes and the
percentage of patients who received rTPA or endovascu-
lar treatment were higher in the study group. Baseline
DWI lesion volume was 17 (3-42) (medians, (first and
third quartile). Day 1 DWI lesion volume was 20 (5-46)
ml, FLAIR was 27 (4-76) ml and lesion growth volume
was 9 (1-39) ml.
Table 1 Demographics, vascular risk factors, stroke
subtypes, biochemical and clinical data, admission
medication and treatment of the study population
Demographics
Age, yr
62 ± 14
Gender (% female) 9 (53%)
Race (% Caucasians) 4 (24%)
NIHSS on admission 10 ± 8
Pre-admission modified Rankin Scale 1 ± 1
Cardiovascular risk factors
Hypertension
14 (82%)
DM 10 (59%)
Hyperlipidemia 7 (41%)
CAD 4 (24%)
AF 6 (35%)
Previous stroke 2 (12%)
Smoking 2 (12%)
ETOH 3 (18%)
Former cancer 2 (12%)
Illicit drug 1 (6%)
Previous ICH 1 (6%)
Biochemical parameters
WBC number (× 10
3/μL)
8.5 ± 3.9
RBC number (×10
9/μL) 4.56 ± 0.85
Hb, mg/dL 13.2 ± 2.7
Ht, % 39.9 ± 7.2
SBP, mmHg 153 ± 33
DBP, mmHg 88 ± 18
Glucose level, mg/dl 179 ± 107
Platelets number (×10
9/μL) 265 ± 63
INR 1.1 ± 0.3
Medication on admission
Statins
5 (29%)
Aspirin 6 (35%)
Coumadin 2 (12%)
ACE blockers 4 (24%)
ARB Βeta-blockers Insulin 3 (18%) 5 (30%) 3 (18%)
Intervention/rtPA (IV) 5/3 (29%/18%)
Data are represented as mean ± SD or %.
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patients
Descriptive data on temporal profiles of biomarkers in
acute patients are presented in the Table 2. E- selectin was
the only one biomarker that decreased (p < 0.039, Wil-
coxon signed rank test) on day 3 in the group of stroke
patients compared to day 1. EPC subsets in the stroke
population were quantified at day 1, as follows: 0.02%
(0.01-0.04) CD133
+CD34
+, 0.01% (0.001-0.02) CD133
+VEGFR2
+, 0.002% (0.0006-0.004) CD34
+VEGFR2
+ and
0.0009% (0.0003-0.0018) CD34
+CD133
+VEGFR2
+ (med-
ians and first and third quartile). Detailed information
about characteristics of EPC subsets is presented else-
where [5].
Correlations between biomarkers and EPC in acute stroke
patients
CD133+CD34+ subsets inversely strongly correlated
with serum ICAM-1 level on day 1 (r = -0.6, p < 0.01),
(Figure 1) and on day 3 (r = -0.967, p < 0.001), (Figure 2),
although, no correlations between EPC and other biomar-
kers were observed on both days.
On day 3, the correlations between CD133+CD34+ and
ICAM-1 remained significant after adjustment for age and
NIHSS (beta -0.992, p < 0.004), for glucose and systolic
blood pressure (SBP) (beta -0.86, p < 0.005), and for white
blood cells (WBC) and hematocrit (beta -1.057, p <
0.0001). However, these adjustments resulted in loss of
correlation between CD133+CD34+ and ICAM-1 on day
1. In addition, similar models of adjustment led to loss in
significance of the correlations between IL-6 and ET-1,
and MMP-9, and MMP-9/TIMP-1.
Correlations between biomarkers and lesion volume
A td a y1 ,D W Ia c u t el e s i o nv o l u m es t r o n g l yc o r r e l a t e d
with MMP-9 (r = 0.509, p < 0.037), (Figure 3), and
MMP-9/TIMP-1(r = 0.59, p < 0.013), (Figure 4). No
correlations between other biomarkers on day 1 and
acute or final lesion volumes were found.
Association of biomarkers with patients’ demographics,
stroke severity, risk factors and medication
Admission NIHSS strongly correlated with day 1 IL-6
(r = 0.624, p < 0.01) and with MMP-9/TIMP-1 (r =
0.523, p < 0.038). No influence of sex, race, hypertension,
DM, hyperlipidemia, CAD, AF and smoking on biomar-
kers was found. Among risk factors, presence of previous
stroke was associated with decreased levels of E-selectin
(z -2.236, p = 0.015, Mann-Whitney). However, only two
patients had a previous stroke, those patients had lower
levels of E-selectin (median 42, range 37-47, n = 2) than
Table 2 Descriptive statistics (median and range) and
Wilcoxon signed rank test of the biomarkers measured
on Day 1 and Day 3 in the stroke patients
Day 1 Day 3 Z P <
Plasma TNF-a, pg/mL 0.7 (0-12) 0.9 (0-32) -1.836 0.07
Plasma IL-6, pg/mL 9 (0-58) 8 (0.4-100) -0.628 0.5
Plasma ET-1, pg/mL 7 (7-18) 9 (5-17) -0.968 0.3
Serum E-selectin, ng/mL 61 (36-77) 52 (43-65) -2.062 0.04*
Serum ICAM-1, ng/mL 233 (14-403) 200 (18-293) -0.157 0.9
Serum VCAM-1, ng/mL 642 (427-1125) 655 (47-1165) -1.098 0.3
Serum MMP-9, ng/mL 398 (0-1384) 438 (292-542) -0.178 0.8
Serum TIMP-1, ng/mL 264(195-540) 285 (153-376) -1.067 0.3
MMP-9/TIMP-1 1.3 (0-4.8) 1.4 (0.2-5.8) -0.267 0.8
*P < 0.05.
Figure 1 Scatterplot of serum soluble ICAM-1 and circulating
CD34+CD133+ EPC on day 1 in the cohort of stroke patients
(Spearman r = -0.6, p < 0.01, n = 17, with 95% CI).
Figure 2 Scatterplot of serum soluble ICAM-1 and circulating
CD34+CD133+ EPC on day 3 (Spearman r = -0.967, p < 0.001,
n = 9 with 95% CI) in the stroke patients.
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51-77, n = 15). Accordingly, these data have to be inter-
preted with caution.
Discussion
The major findings of our pilot study are: 1) consistent
inverse correlation between circulating EPC and soluble
ICAM-1, 2) correlation of acute DWI lesion volume with
day 1 MMP-9 and MMP-9/TIMP-1 ratio, 3) association
of admission NIHSS with day 1 IL-6 and MMP-9.
We measured soluble ICAM-1, which is easily assessa-
ble in clinical setting. It shown to be proportional to cel-
lular ICAM-1, which is expressed on endothelial cells
[24] and, therefore, soluble ICAM-1 may most likely
reflect endothelial function. Up-regulation of ICAM-1 is
an essential step mediating transmigration of leukocytes
through perturbed endothelium and exacerbating reper-
fusion injury [25]. Up-regulation of endothelial expres-
sion of ICAM-1 is shown in acute ischemic brain tissue
in humans [26]. Increase of ICAM-1 is linked to stroke-
related neurological deterioration [27], and poor short-
term stroke prognosis [15]. The most important finding
in the study is the link between high ICAM-1 and low
levels of circulating CD133+CD34+ EPC in early stroke.
EPC represent a cumulative index of cerebrovascular
function [7], and are decreased in severe atherosclerosis
[8], in patients with increased cardiovascular risk [7],
and in severe strokes [5]. The precise mechanism of this
association remains to be determined; however, a recep-
tor ICAM-1/CD18 is shown to be expressed on EPC
and plays an essential role in their recruitment [28].
Importantly, this subset CD133
+CD34
+ represents
immature population of strongly proliferating progenitor
cells, and is co-expressed in hematopoietic progenitors
[29]. Previous experimental studies showed a plateau in
expression of ICAM-1 by endothelial cells after TNF-a
activation between days 1-3 [24], and after the stroke
onset a persistency in soluble ICAM-1 levels on days 1,
3 and 14 [17] was detected; our follow-up data on day 3
is in line with these findings. The main impact of our
study is an attempt to identify factors, which contribute
to the impaired EPC mobilization in stroke. A recent
study showed an association between high ET-1 levels
and low EPC mobilization after acute myocardial infarc-
tion [30]. Temporal profiles of EPC in acute stroke and
AMI share similar patterns [6,31]. Both ET-1 and
I C A M - 1a r ec o n s i d e r e dt ob ei m p o r t a n tm a r k e r so f
endothelial dysfunction. We failed to show a correlation
between low EPC and high ET-1 in our stroke cohort.
However, our study in own way supports the reported
observation [30] emphasizing that endothelial dysfunc-
tion can be related to impaired neovascularization car-
ried out by EPC.
In our stroke cohort, day 1 MMP-9 and MMP-9/TIMP-
1 ratio correlated with acute DWI lesion volumes. Acute
lesion volumes are linked with clinical stroke severity [32]
and widely used for outcome prediction. Our findings are
in accordance with numerous clinical studies showing
associations of MMP-9, responsible for degradation of
basal lamina and extracellular matrix components, with
increased hemorrhagic transformation in acute stroke
[33], BBB disruption [20] and worse outcomes [19].
Increased levels of pro-inflammatory IL-6 are corre-
lated with acute infarct volume measured on computed
tomography (CT) and with stroke outcome measured by
modified Rankin scale (mRs) at 3 months [18]. Increase
of IL-6 is associated with early neurological worsening
[34], and with 3 month poor outcome (mRs 3-5, death
Figure 3 Scatterplot of baseline lesion volume and day 1 total
serum MMP-9 (Spearman r = 0.509, p < 0.037, n = 17 with
95% CI) in the stroke patients.
Figure 4 Scatterplot of baseline lesion volume and day 1
MMP-9/TIMP-1 (Spearman (r = 0.59, p < 0.013, n = 17 with
95% CI) in the stroke patients.
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findings, although our stroke cohort did not include
many severe stroke patients.
Focal ischemia initiates an inflammatory response,
which amplifies growth of ischemic lesion in acute
phase of stroke [2,3,14]. The detected high ICAM-1
level, an important marker of neuroinflammation, is
associated with low levels of EPC in early stroke, which
supports our hypothesis that early inflammation inhibits
neovascularization. The findings also suggest that com-
bination of both markers may be useful for stroke out-
come prediction in clinical s e t t i n g .H o w e v e r ,al a r g e r
prospective study is needed to confirm our findings.
The major limitation of the study is a small sample size.
On the other hand, we carefully selected patient popula-
tion excluding any indication of underlying inflamma-
tory condition. Other limitations of the study include
absence of the age- and sex- matched controls.
Conclusion
High levels of ICAM-1 are linked to low levels of
CD133+CD34+ subset of EPC. Our findings also sup-
port the hypothesis that biomarkers of neuroinflamma-
tion and remodeling are related to severity of tissue
injury in early ischemia.
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